Literature DB >> 9564003

Recombinant factor VIII may not abolish risk of new variant CJD from factor VIII.

J P Betts.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9564003      PMCID： PMC1113082          DOI： 10.1136/bmj.316.7141.1385

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.

Authors:  E Aygören-Pürsün; I Scharrer
Journal:  Thromb Haemost       Date:  1997-11       Impact factor: 5.249

2.  Blood transfusion risk: protecting against the unknown.

Authors:  J Barbara; P Flanagan
Journal:  BMJ       Date:  1998-03-07

3.  Virus safety considerations for recombinant factor VIII (rFVIII, Kogenate).

Authors:  D Arnold
Journal:  Haemophilia       Date:  1995-04       Impact factor: 4.287

4.  Notes to applicants for marketing authorizations on the production and quality control of medicinal products derived by recombinant DNA technology. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy.

Authors: 
Journal:  J Biol Stand       Date:  1989-07

5.  Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent.

Authors:  M E Bruce; R G Will; J W Ironside; I McConnell; D Drummond; A Suttie; L McCardle; A Chree; J Hope; C Birkett; S Cousens; H Fraser; C J Bostock
Journal:  Nature       Date:  1997-10-02       Impact factor: 49.962
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.